Mustafa Özdoğan, MD X Hesabı İstatistikleri

X Hesabı

http://x.com/ozdogan_md

Son Kontrol : 15.08.2025

Takipçisi 6.588

Takip Edilen 968

Sektör

Tweetler	Beğeni	Retweet	Etkileşim
We often focus on breakthrough drugs & groundbreaking trials. 👩‍⚕️ But sometimes, adding just 1 dedicated oncology pharmacist to the team can: ✅ Cut adverse drug reaction (ADR) risk by 62% ⚠️ Reduce severe ADRs by 75% 🔍 Detect 2.6× more...	8	2	%0,27
🚨 Unexpected pancreatic cancer trial results (GENERATE/JCOG1611): Nab-paclitaxel + gemcitabine outperformed mFOLFIRINOX & S-IROX in OS (17.1 vs 14.0 & 13.6 mo). Why? 🔹 Better 2L options (liposomal irinotecan) → longer PPS 🔹 Fewer toxicities →...	17	5	%0,59
🚨 FDA grants accelerated approval to oral zongertinib for advanced HER2 TKD-mutant NSCLC. 📊 ORR: 75%, 58% with responses ≥6 months 💊 More manageable side effects vs. traditional HER2-targeted ADCs Details: https://t.co/xLeYPtnY6X #LungCancer...	32	10	%1,19

Tweetler	Tarih	Beğeni	Retweet	Etkileşim

Tweetler	Tarih	Beğeni	Retweet	Yorum	Görüntülenme

Takipçi : 6.588

Web sitesi : https://t.co/5DClntnZdr

Kullanıcı : ozdogan_md

Tanıtım :

Sayfa ile ilgili istek ve şikayetleriniz için aşağıdaki formu kullanabilirsiniz.